DNA RNA and Cells

08 Aug 2023 Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
05 Aug 2023 Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
05 Aug 2023 Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
03 Aug 2023 Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
03 Aug 2023 Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease
03 Aug 2023 BlueRock Therapeutics and bit.bio announce collaboration and option agreement for the discovery and manufacture of regulatory T cell (Treg) based therapies
03 Aug 2023 AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
02 Aug 2023 Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
02 Aug 2023 Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma
01 Aug 2023 TransCode Therapeutics Announces Positive Results in Non-human Primates with its Lead Therapeutic Candidate, TTX-MC138
01 Aug 2023 Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
30 Jul 2023 4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
28 Jul 2023 Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
27 Jul 2023 Krystal Biotech Announces Pipeline Expansion into Oncology and FDA Acceptance of IND Application for Lead Oncology Candidate KB707
25 Jul 2023 Replay and MD Anderson announce FDA clearance of IND application for first-in-class T-Cell Receptor Natural Killer (TCR-NK) cell therapy for multiple myeloma
25 Jul 2023 EpiBone to Start Clinical Trials for Knee Cartilage Grown in Lab
25 Jul 2023 AvenCell Therapeutics Announces EMA Approval of Clinical Trial Application (CTA) for AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hemato
25 Jul 2023 NK:IO Raises £1.2M, Bringing Total Seed Funding to £5.1M, to Advance Pioneering NK Cell Therapy
25 Jul 2023 BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected
24 Jul 2023 Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
22 Jul 2023 Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
19 Jul 2023 Yikaida CAR-T Cell Therapy Approved as a Second-line Therapy for New Indication
19 Jul 2023 Qihan Biotech Announces NMPA Approval of Investigational New Drug (IND) Application for QN-019a, a Multi-locus Gene-Editing Cell Therapy Product to treat CD19-positive B-Cell Lymphoma
19 Jul 2023 Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe
18 Jul 2023 NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimer’s Association International Conference

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up